- Home
- PFSA vs NRXS Comparison
PFSA vs NRXS Comparison
Compare PFSA & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFSA
- NRXS
- Stock Information
- Founded
- PFSA 2009
- NRXS 2011
- Country
- PFSA United States
- NRXS United States
- Employees
- PFSA N/A
- NRXS N/A
- Industry
- PFSA Medical/Dental Instruments
- NRXS
- Sector
- PFSA Health Care
- NRXS
- Exchange
- PFSA Nasdaq
- NRXS Nasdaq
- Market Cap
- PFSA 25.1M
- NRXS 25.0M
- IPO Year
- PFSA N/A
- NRXS 2023
- Fundamental
- Price
- PFSA $0.31
- NRXS $2.43
- Analyst Decision
- PFSA
- NRXS Strong Buy
- Analyst Count
- PFSA 0
- NRXS 1
- Target Price
- PFSA N/A
- NRXS $7.00
- AVG Volume (30 Days)
- PFSA 6.7M
- NRXS 52.6K
- Earning Date
- PFSA 08-14-2025
- NRXS 08-12-2025
- Dividend Yield
- PFSA N/A
- NRXS N/A
- EPS Growth
- PFSA N/A
- NRXS N/A
- EPS
- PFSA N/A
- NRXS N/A
- Revenue
- PFSA $75,000.00
- NRXS $3,217,531.00
- Revenue This Year
- PFSA N/A
- NRXS $62.14
- Revenue Next Year
- PFSA N/A
- NRXS $131.87
- P/E Ratio
- PFSA N/A
- NRXS N/A
- Revenue Growth
- PFSA 66.67
- NRXS 41.93
- 52 Week Low
- PFSA $0.30
- NRXS $1.33
- 52 Week High
- PFSA $5.50
- NRXS $6.20
- Technical
- Relative Strength Index (RSI)
- PFSA N/A
- NRXS 46.52
- Support Level
- PFSA N/A
- NRXS $2.35
- Resistance Level
- PFSA N/A
- NRXS $2.68
- Average True Range (ATR)
- PFSA 0.00
- NRXS 0.13
- MACD
- PFSA 0.00
- NRXS 0.01
- Stochastic Oscillator
- PFSA 0.00
- NRXS 41.59
About PFSA Profusa Inc. Common Stock
Profusa Inc is a digital health technology company based in Emeryville, CA, that has developed a real-time, consumer-friendly platform that is designed to measure an individual's biochemistry, be easy to use, be cost-effective, and provide the necessary data to manage chronic disease and health and wellness decisions to improve health outcomes for a large population of potential users. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).